首页> 外文期刊>Research and Reviews in BioSciences >Lycopene ameliorates atherogenic cardiovascular risk in streptozotocin-induced diabetic hyperlipidaemia in wistar rats
【24h】

Lycopene ameliorates atherogenic cardiovascular risk in streptozotocin-induced diabetic hyperlipidaemia in wistar rats

机译:番茄红素改善链脲佐菌素诱导的wistar大鼠糖尿病高脂血症的动脉粥样硬化性心血管风险

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The aim of the study was conducted to investigate the ameliorative effects of lycopene in atherogenecity of streptozotocin-induced diabetic hyperlipidaemia in Wistar rats. Thirty (30) Wistar rats of which twenty of them were made diabetic by single intraperitoneal injection of 60 mg/kg b w of streptozocin. After which the diabetic animals were randomly divided into the following groups: Groups (I, II, III, IV, V and VI). Group I and II (NC + 0.5 ml of olive oil asn DC + 0.5 ml of olive oil), while Group III-V (received 10, 20 and 40 mg/kg b w of lycopene) and Group VI (received 2 mg/kg b w of glibenclamide). All administration was by oral gavage and it lasted for four weeks. After the last day of treatment, blood sample was collected and serum separated and used for determination of serum lipid profile. Atherogenic indices and cardiac risk ratio were calculated. There was a significant (P < 0.05) dose dependent reduction blood in glucose level with an increase of insulin concentration which was notstatistically significantly when compared with diabetic control rats. The results showed a significantly (P < 0.05) decreased serum levels of total cholesterol, triglyceride and low-density lipoprotein with a corresponding elevated serum high-density lipoprotein level in diabetic-lyccopene treated animals in comparison with the diabetic control group. Serum atherogenic risk predictor indices (LDL-cholesterol/ HDL-cholesterol, and log (TRIG/HDL-cholesterol) and cardiac risk ratio were significantly deceased (P < 0.05) while HDL-cholesterol/TC was increased significantly (P < 0.05) when compared with diabetic control group. The experimental animals also showed a significantly (P < 0.05) increased percentage protections especially with the highest dose of lycopene recording the highest increased protection. From the available evidence in this study it can be concluded that lycopene ameliorated atherogenic diabetic-indued dyslipidaemia, hence may have cardio-pro-tective effects due to their high antioxidant activity.
机译:进行该研究的目的是研究番茄红素对链脲佐菌素诱导的糖尿病性高脂血症大鼠的动脉粥样硬化性的减轻作用。通过单次腹膜内注射60 mg / kg b w链佐星使30(30)只Wistar大鼠成为糖尿病。之后,将糖尿病动物随机分为以下几组:组(I,II,III,IV,V和VI)。第I和II组(NC + 0.5 ml橄榄油,DC + 0.5 ml橄榄油),第III-V组(番茄红素的重量为10、20和40 mg / kg体重)和VI组(收到2 mg / kg bw格列本脲)。所有给药都是通过口管进行的,持续了四个星期。在治疗的最后一天之后,收集血液样品并分离血清并用于测定血清脂质谱。计算动脉粥样硬化指数和心脏风险比。血糖水平存在显着(P <0.05)的剂量依赖性降低血糖水平,且胰岛素浓度增加,与糖尿病对照组相比,这没有统计学意义。结果显示,与糖尿病对照组相比,糖尿病-lyccopene治疗组动物的总胆固醇,甘油三酯和低密度脂蛋白的血清水平显着降低(P <0.05),血清高密度脂蛋白水平相应升高。血清动脉粥样硬化风险预测指标(LDL-胆固醇/ HDL-胆固醇)和log(TRIG / HDL-胆固醇)和心脏风险比显着降低(P <0.05),而HDL-胆固醇/ TC显着升高(P <0.05)与糖尿病对照组相比,实验动物还显示出显着(P <0.05)的保护百分比增加,尤其是番茄红素的最高剂量记录了最高的保护增加,从这项研究中的现有证据可以得出结论,番茄红素改善了动脉粥样硬化性糖尿病-血脂异常,由于其高抗氧化活性而可能具有心脏保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号